A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study).
Phase of Trial: Phase IV
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 19 Oct 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 19 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.